Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Recruiting
N/A
Interventional Study
Fibrotic Interstitial Lungs Diseases
Idiopathic Pulmonary Fibrosis (IPF)
Progressive Pulmonary Fibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Katerina M. Antoniou · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is str…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.
* The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care…
Contacts
Eirini Vasarmidi, MD MSc PhD, Ass. Professor
CONTACT